Physicians Don’t Always Recognize Patients’ Radiation Therapy Side Effects

A new study finds that significant symptoms in young and Black patients are more likely to be under-recognized.

9:00 AM

Author | Nicole Fawcett

Radiation therapy of young women breast cancer

Physicians did not recognize side effects from radiation therapy in more than half of breast cancer patients who reported a significant symptom, a new study finds.

The study compared reports from 9,941 patients from practices across the state of Michigan who received radiation therapy following lumpectomy. Patients filled out standard symptom reporting tools for four common side effects during their radiation treatment: pain, itchy skin, swelling and fatigue. At the same time, physicians assessed patients' symptoms using a standardized tool called the Common Toxicity Criteria for Adverse Events.

LISTEN UP: Add the new Michigan Medicine News Break to your Alexa-enabled device, or subscribe to our daily updates on iTunes, Google Play and Stitcher

Researchers compared these two sets of symptom reports and found incidences where physicians reported no issue even though patients reported substantial concerns. This under-recognition occurred in 31% of patients reporting pain, 37% of patients with itchy skin, 51% of patients with swelling and 19% of patients with fatigue.

"Physicians sometimes miss when their patients are having substantial symptoms. Recognizing side effects is critical for physicians to provide supportive care to help patients manage their symptoms," says study author Reshma Jagsi, M.D., D.Phil., Newman Family Professor and deputy chair of radiation oncology at Michigan Medicine.

Recognizing side effects is critical for physicians to provide supportive care to help patients manage their symptoms.
Reshma Jagsi, M.D., D. Phil.

Jagsi will present the findings at the 2020 San Antonio Breast Cancer Symposium. The study included 29 practices throughout Michigan as part of the Michigan Radiation Oncology Quality Consortium, a collaborative quality initiative funded by Blue Cross Blue Shield of Michigan and the Blue Care Network.

The study found that side effects were more likely to be missed in younger patients and Black patients, suggesting that better methods to detect symptoms in these patients could help reduce disparities in patient experiences and outcomes.

"If physicians are less likely to pick up on symptoms that Black patients are experiencing, this might help explain why their symptoms become so severe and also might guide us toward interventions to reduce race-based disparities in experiences of cancer treatment," says Jagsi, a member of the University of Michigan Rogel Cancer Center.

The team proposes additional research to understand why certain populations are more likely to have symptoms missed and how to overcome any issues of misconceptions or mistrust between patients and providers.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

"Patient-reported outcomes provide an important complement to physician evaluations. Improving symptom detection may be a targetable mechanism to reduce disparities in cancer treatment experiences and outcomes, at least in the setting of breast radiation therapy," Jagsi says.

Additional authors are Kent A. Griffth, Frank Vicini, Thomas Boike, Michael

Dominello, Gregory Gustafson, James A. Hayman, Jean M. Moran, Jeffrey Radawski, Eleanor Walker and Lori J. Pierce.

MROQC is funded by Blue Cross Blue Shield of Michigan and the Blue Care Network as part of the BCBSM Value Partnership program.


More Articles About: Industry DX Breast cancer Radiation Oncology Breast Cancer Treatment Cancer Pain Cancer Research Cancer: Cancer Types
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories person with stomach pain purple and grey coloring and at home stool test
Health Lab
When to use an at-home colorectal cancer screening test instead of a colonoscopy
What to know about an at-home colorectal cancer screening test versus a colonoscopy.
cup sample with orange top in front of toilet
Health Lab
Urine-based test detects aggressive prostate cancer
Researchers at have validated a previously developed urine test, which can potentially bypass invasive procedures for prostate cancer detection among men who are unlikely to benefit. 
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
Using biolasers to improve cancer diagnostic tools
Lighting up cancer cells with biolasers. The technique overcomes the limitations of current cancer diagnostic tools. For more on this story and for others like it, visit the Health Lab website where you can subscribe to our Health Lab newsletters to receive the latest in health research and information to your inbox each week. Health Lab is a part of the Michigan Medicine Podcast Network, and is produced by the Michigan Medicine Department of Communication. You can subscribe to Health Lab on Apple Podcasts, Spotify, or wherever you listen to podcasts.
PURPLE BLUE RED CELLS FLOATING
Health Lab
Using cellular therapy to treat cancer, and beyond
Here, Monalisa Ghosh, M.D., a hematologist-oncologist at the University of Michigan Health Rogel Cancer Center, answers questions about cellular therapy; how it's used and what exciting developments are soon to come.
patient looking at paper with provider in scrubs blue in clinic
Health Lab
How race impacts patients’ response to cancer immunotherapy
The first large scale analysis finds immune checkpoint inhibitors are equally effective in Black and white patients, with Black patients having fewer side effects.
bone close up of cells inside green bbble with cells inside in yellow brown pink and red orange background
Health Lab
How breast cancer cells survive in bone marrow after remission
A new study from researchers at the University of Michigan and the University of California San Diego has shed light on a previously poorly understood aspect of breast cancer recurrence: how cancer cells survive in bone marrow despite targeted therapies.